Literature DB >> 7031501

Hypokalemic periodic paralysis exacerbated by acetazolamide.

C F Torres, R C Griggs, R T Moxley, A N Bender.   

Abstract

Although acetazolamide usually prevents paralytic attacks in hypokalemic periodic paralysis, not all patients benefit from this treatment. We studied a father and two sons in whom attack frequency and severity increased on acetazolamide. Administration of triamterene virtually abolished attacks in three separate single-blind trials totaling more than 12 months. Spontaneous and glucose-insulin provoked occurred with only slight hypokalemia. Acetazolamide produced slight hypokalemia and provoked attacks of weakness whereas triamterene increased potassium levels significantly. Certain patients with hypokalemic periodic paralysis are worsened by acetazolamide, perhaps because of its kaliopenic effect. Triamterene may be effective in some of these patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031501     DOI: 10.1212/wnl.31.11.1423

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Channelopathies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Treatment and management of neuromuscular channelopathies.

Authors:  Lydia Sharp; Jaya R Trivedi
Journal:  Curr Treat Options Neurol       Date:  2014-10       Impact factor: 3.598

3.  A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G).

Authors:  June Bum Kim; Kyung Yil Lee; Jae Kyun Hur
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

Review 4.  Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder.

Authors:  Bertrand Fontaine; Emmanuel Fournier; Damien Sternberg; Savine Vicart; Nacira Tabti
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 5.  Skeletal Muscle Channelopathies.

Authors:  Lauren Phillips; Jaya R Trivedi
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

6.  Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.

Authors:  Fenfen Wu; Wentao Mi; Stephen C Cannon
Journal:  Brain       Date:  2013-10-18       Impact factor: 13.501

7.  Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity.

Authors:  Koushik Choudhury; Tagore S Bandaru; Mohamed A Fouda; Kaveh Rayani; Mohammad-Reza Ghovanloo; Radda Rusinova; Tejas Phaterpekar; Karen Nelkenbrecher; Abeline R Watkins; Damon Poburko; Jenifer Thewalt; Olaf S Andersen; Lucie Delemotte; Samuel J Goodchild; Peter C Ruben
Journal:  J Gen Physiol       Date:  2021-05-03       Impact factor: 4.086

8.  Skeletal muscle na channel disorders.

Authors:  Dina Simkin; Saïd Bendahhou
Journal:  Front Pharmacol       Date:  2011-10-14       Impact factor: 5.810

Review 9.  Review of the Diagnosis and Treatment of Periodic Paralysis.

Authors:  Jeffrey M Statland; Bertrand Fontaine; Michael G Hanna; Nicholas E Johnson; John T Kissel; Valeria A Sansone; Perry B Shieh; Rabi N Tawil; Jaya Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Muscle Nerve       Date:  2017-11-29       Impact factor: 3.217

10.  The genotype and clinical phenotype of Korean patients with familial hypokalemic periodic paralysis.

Authors:  June Bum Kim; Man Ho Kim; Soon Ju Lee; Dae Joong Kim; Byung Churl Lee
Journal:  J Korean Med Sci       Date:  2007-12       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.